Several reports suggest that the development of resistance to doxorubicin involves cancer cells that acquire multidrug-resistant phenotypes [10], populations (CD44+/CD24 −/low) of breast cancer stem cells (CSCs) [11, 12], and initiation of the epithelial-mesenchymal transition (EMT) [13]. This evidence concerns the gene CD24 and breast carcinoma.